Unichem Laboratories Faces ₹93.66 Crore GST Order, Plans Appeal

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Unichem Laboratories Faces ₹93.66 Crore GST Order, Plans Appeal

Unichem Laboratories Limited has disclosed receipt of an order from the Commissioner (Appeals), Thane involving a penalty of ₹87.07 crore and interest liability of ₹6.59 crore related to the cross-charge of common services under the CGST and Maharashtra SGST Acts. The company said it will challenge the order through an appeal and currently expects no material impact on its financial, operational or other activities.

Unichem Laboratories to Challenge ₹93.66 Crore GST Order

Total liability in the order: Approximately ₹93.66 crore
Penalty: ₹87.07 crore | Interest: ₹6.59 crore

Reader Takeaway: Company will appeal the order; legal outcome remains the key monitor.

What just happened

Unichem Laboratories Limited informed the exchanges that it has received an order from the Commissioner (Appeals), Thane.

The order relates to the cross-charge of common services and alleges delayed payment of tax liability for supplies under the provisions of the Central Goods and Services Tax Act, 2017 and the corresponding Maharashtra State Goods and Services Tax Act.

According to the order, the company faces an interest liability of ₹6.59 crore and a penalty of ₹87.07 crore, taking the total amount involved to approximately ₹93.66 crore.

The company received the order on September 18, 2026.

Why this matters

The order involves a sizeable tax-related demand and legal proceedings that investors will need to monitor.

However, Unichem Laboratories has stated that, based on legal advice, it intends to challenge the order and does not currently expect any material impact on its financial position, operations or other business activities.

What changes now

The company plans to file an appeal within the prescribed statutory timelines.

Until the appellate process progresses, the matter remains a legal dispute rather than a concluded financial liability.

Risks to watch

Investors should monitor:

  • Filing and admission of the company's appeal.
  • Any stay or interim relief granted by appellate authorities.
  • Future regulatory disclosures on the litigation.
  • Any accounting provisions or contingent liability disclosures in subsequent financial statements.

What to track next

The next important development will be the company's appeal against the order and any subsequent judicial or appellate decisions that determine the final liability, if any.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.